Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of namodenoson in advanced pancreatic cancer
MOH_2024-01-15_013185Phase 2Not yet recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of namodenoson in pancreatic cancer (PC), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: Safety and tolerability and Antitumor activity. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
namodenoson
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on MOH_2024-01-15_013185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-15_013185.